Roche (VTX:ROG) received a CHF 260 target price from research analysts at UBS Group in a research report issued to clients and investors on Monday, January 8th, www.boersen-zeitung.de reports. The firm currently has a “neutral” rating on the healthcare company’s stock. UBS Group’s price objective would indicate a potential upside of 15.99% from the company’s current price.
ROG has been the subject of a number of other research reports. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a “buy” rating in a report on Thursday, October 12th. Morgan Stanley set a CHF 260 price target on Roche and gave the stock a “neutral” rating in a report on Friday, November 17th. Deutsche Bank set a CHF 264 price target on Roche and gave the stock a “neutral” rating in a report on Tuesday, December 12th. JPMorgan Chase & Co. reissued a “buy” rating and issued a price target on shares of Roche in a report on Monday, October 16th. Finally, Liberum Capital set a CHF 279 price target on Roche and gave the stock a “buy” rating in a report on Wednesday, November 22nd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of CHF 258.90.
Roche (VTX ROG) traded up CHF 1.05 during mid-day trading on Monday, hitting CHF 224.15. The stock had a trading volume of 2,940,000 shares, compared to its average volume of 1,700,000. The firm has a market capitalization of $193,320.00 and a price-to-earnings ratio of 19.92. Roche has a fifty-two week low of CHF 221.15 and a fifty-two week high of CHF 273.
ILLEGAL ACTIVITY NOTICE: “Roche (VTX:ROG) Given a CHF 260 Price Target by UBS Group Analysts” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/03/roche-rog-pt-set-at-chf-260-by-ubs-group.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.